---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-004866"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:03:27.278188+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics reports $47.9M cash; Phase 3 uproleselan trial continues to final events in H1 2024

## Summary
- Cash and equivalents $47.9M at Dec 31, 2022; raised $28.7M net from ATM in Q1 2023.
- R&D expenses fell to $5.9M in Q4 2022 from $12.9M in Q4 2021; full-year R&D $28.4M vs $47.5M.
- DMC recommended Phase 3 uproleselan trial continue after interim utility analysis; final OS events expected H1 2024.
- Appointed Edwin Rock as CMO, Bruce Johnson as CCO, and Chinmaya Rath as CBO in 2022-2023.
- Cash runway projected to fund operations to end of 2024.

## SEC filing metadata
- accession: 0001558370-23-004866
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/0001558370-23-004866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/glyc-20230329x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-004866
- JSON: https://secwatch.observer/filing/0001558370-23-004866.json
- Plain text: https://secwatch.observer/filing/0001558370-23-004866.txt

## Key facts
- Earnings Releases
  CRESCENT BIOPHARMA, INC. reported financial results for quarter and year ended December 31, 2022.
  - Period: quarter and year ended December 31, 2022
  - Result: reported results
  source text: GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/0001558370-23-004866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.